Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study

Quantification of emicizumab by mass spectrometry in plasma of people with hemophilia A: A method validation study

Abstract Background Emicizumab is a new treatment option for people with hemophilia A. Emicizumab was approved with a body‐weight‐based dosage regimen, without laboratory monitoring requirements. Guidelines, however, recommend measuring emicizumab concentrations when the presence of antidrug antibod...

Full description

Bibliographic Details
Main Authors: Anouk A. M. T. Donners, László Gerencsér, Kim C. M. van derElst, Toine C. G. Egberts, Moniek P. M. deMaat, Albert Huisman, Rolf T. Urbanus, Mohsin El Amrani
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
drug monitoring
emicizumab
hemophilia A
mass spectrometry
validation study
Online Access:https://doi.org/10.1002/rth2.12725

Internet

https://doi.org/10.1002/rth2.12725

Similar Items